CG
PCRX icon

Cutler Group’s Pacira BioSciences PCRX Stock Holding History

Cutler Group’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,500
Closed -$20K – 5346
2022
Q2 		$20K Buy
+1,500
New +$98.3K ﹤0.01% 2680
2019
Q2 		– Sell
-1,000
Closed -$5K – 4655
2019
Q1 		$5K Sell
1,000
-2,500
-71% -$97.6K ﹤0.01% 2930
2018
Q4 		$2K Hold
3,500
– – ﹤0.01% 3405
2018
Q3 		$2K Buy
+3,500
New +$151K ﹤0.01% 3544
2018
Q2 		– Sell
-48,000
Closed -$100K – 4688
2018
Q1 		$100K Buy
48,000
+42,200
+728% +$1.5M 0.01% 1176
2017
Q4 		$26K Buy
5,800
+5,000
+625% +$198K ﹤0.01% 2344
2017
Q3 		$5K Sell
800
-5,800
-88% -$233K ﹤0.01% 4407
2017
Q2 		$8K Sell
6,600
-5,400
-45% -$251K ﹤0.01% 4397
2017
Q1 		$31K Sell
12,000
-10,900
-48% -$471K ﹤0.01% 2872
2016
Q4 		$124K Sell
22,900
-14,600
-39% -$487K ﹤0.01% 1715
2016
Q3 		$226K Buy
37,500
+32,500
+650% +$1.27M 0.01% 1104
2016
Q2 		$95K Sell
5,000
-4,300
-46% -$211K ﹤0.01% 1734
2016
Q1 		$141K Buy
9,300
+2,300
+33% +$135K 0.01% 1293
2015
Q4 		$53K Buy
+7,000
New +$396K ﹤0.01% 2390

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.85B AUM 15.7% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Cutler Group's PCRX Position: Q3 2022 in Review

Cutler Group sold out of Pacira BioSciences (PCRX) in Q3 2022, closing a stake of 100 shares — an estimated $5K sold.

Cutler Group first reported a position in PCRX in Q4 2015 and held it in 11 quarters. The position peaked at $731K in Q4 2016. 272 funds tracked by Wall St. Rank hold PCRX as of Q3 2022.

  • Cutler Group reported no remaining Pacira BioSciences position as of Q3 2022 after selling out during the quarter.
  • Cutler Group sold 100 Pacira BioSciences shares in Q3 2022, an estimated $5K.
  • Cutler Group first reported a position in Pacira BioSciences in Q4 2015 and held it in 11 quarters.
  • Cutler Group's Pacira BioSciences position peaked at $731K in Q4 2016.
  • 272 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2022.

Based on Cutler Group's 13F filing for Q3 2022, filed 25 Oct 2022.